ASRT - Assertio Therapeutics, Inc.
3.4000 0.00 (0.00%)
After hours: 4:58PM EDT
| Previous Close | 3.4300 |
| Open | 3.4300 |
| Bid | 2.8900 x 4000 |
| Ask | 3.4500 x 1300 |
| Day's Range | 3.3550 - 3.5100 |
| 52 Week Range | 3.0900 - 9.4800 |
| Volume | 549,147 |
| Avg. Volume | 942,485 |
| Market Cap | 218.978M |
| Beta (3Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2590 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.70 |
- Zacks•3 days ago
ASSERTIO THERAPEUTICS Enters Oversold Territory
ASSERTIO THERAPEUTICS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Markit•9 days ago
See what the IHS Markit Score report has to say about Assertio Therapeutics Inc.
Assertio Therapeutics Inc NASDAQ/NGS:ASRTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate Bearish sentimentShort interest | PositiveShort interest is moderate for ASRT with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ASRT are favorable, with net inflows of $1.82 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•9 days ago
Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year?
Is (ASRT) Outperforming Other Medical Stocks This Year?
Motley Fool•14 days agoAssertio Therapeutics, Inc (ASRT) Q1 2019 Earnings Call Transcript
ASRT earnings call for the period ending March 31, 2019.
- Zacks•15 days ago
Assertio (ASRT) Tops Q1 Earnings and Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of 27.78% and 4.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•15 days ago
Assertio: 1Q Earnings Snapshot
On a per-share basis, the Lake Forest, Illinois-based company said it had a loss of 22 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 23 cents per share. The results topped ...
- GlobeNewswire•15 days ago
Assertio Therapeutics Announces First-Quarter 2019 Financial Results
-- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms.
- Zacks•17 days ago
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
- Zacks•22 days ago
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•29 days ago
Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019
LAKE FOREST, Ill., April 24, 2019 -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8,.
- Simply Wall St.•last month
What Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) ROE Can Tell Us
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we...
- Zacks•last month
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
- GlobeNewswire•2 months ago
Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors
Assertio Therapeutics, Inc. (ASRT) announced today that James (Jay) J. Galeota, Jr. has been appointed to the Company’s Board of Directors. Mr. Galeota most recently served as the President and Chief Operating Officer of G&W Laboratories, Inc. “We are thrilled to welcome Jay to our Board of Directors,” said Arthur Higgins, President and CEO of Assertio.
- Reuters•2 months ago
Magellan Health nears board deal with hedge fund Starboard Value - sources
NEW YORK/BOSTON (Reuters) - U.S. healthcare plan and pharmacy benefits manager Magellan Health Inc is nearing an agreement with Starboard Value LP to expand the size of its board by several seats, including a representative from the activist hedge fund, three sources familiar with the matter said on Thursday. Starboard declined to comment. The hedge fund said that although the company operates in an industry that is poised for growth, it has underperformed because of operational missteps and poor capital allocation.
- GlobeNewswire•2 months ago
Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling
LAKE FOREST, Ill., March 28, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in.
- Zacks•2 months ago
Will Assertio Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Assertio Therapeutics.
- GuruFocus.com•2 months ago
Weekly CFO Buys Highlight
Insiders invest in Forterra, HC2 Holdings and Assertio Therapeutics
- Zacks•2 months ago
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
- GuruFocus.com•2 months ago
Assertio Therapeutics Inc (ASRT) Files 10-K for the Fiscal Year Ended on December 31, 2018
Assertio Therapeutics Inc (NASDAQ:ASRT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
